Even though treatment with the anti-VEGF bevacizumab reduces intracellular survivin concentrations in cancer cells and endothelial cells [28], our data suggest that the extracellular, circulating survivin protein does not change due to platinum plus bevacizumab therapy. This evidence concerns the gene VEGFA and cancer.